Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.The Lancet. Oncology|June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.Lancet (London, England)|October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialChristopher C Parker, Noel W Clarke, Adrian D Cook, et al.Pageof 2